Role of Cytochrome P450 Polymorphisms on Breast Cancer Treatment
- *Corresponding Author:
- Alam Z
Executive Research and Development
Orion Pharma Ltd, Dhaka, Bangladesh
E-mail: [email protected]
Received Date: April 04, 2017 Accepted Date: May 11, 2017 Published Date: May 20, 2017
Citation: Majumder T, Sajid I, Arif MH, Alam Z (2017) Role of Cytochrome P450 Polymorphisms on Breast Cancer Treatment. Vitam Miner 6: 157. doi:10.4172/2376-1318.1000157
Copyright: © 2017 Majumder T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Pharmacogenetics is one of the key factors that is responsible for biological signaling variations that can lead to various diseases. Being led by genetic mutations, breast cancer is affected at higher level due to pharmacogenetic variations. Chemotherapeutic drug is mainly bio transformed in the liver by cytochrome P450 (CYP) enzyme. CY450 isoforms and polymorphisms direct inter individual and interethnic variability in pharmacokinetics and pharmacodynamics of drugs. This further leads to alteration in cancer prognosis. This paper discusses clinically used drugs in breast cancer treatment where interethnic differences in drug safety and efficacy are known to exist. Best known anticancer drug for estrogen receptor-positive breast cancer is Tamoxifen and its efficacy depends predominantly on genetic variants of CYP2D6. Other polymorphisms of CYP3A4, CYP3A5, and sulfotransferase1A1 (SULT1A1) also provide important information about mechanism of tamoxifen activity and resistance. Many chemotherapeutics like anthracyclines have also showed association with polymorphism of genes (CBR3, ABCB1, glutathione-related transporter genes, oxidative stress-related genes) and clinical outcomes. Many chemotherapeutic drug including taxanes, gemcitabine, capecitabine/5-fluorouracil, vinorelbine, methotrexate, and cyclophosphamide are being studies for the association of genetic variations with their bioactivity.